We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
-17.44%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$3.87B
AUM Growth
-$961M
Cap. Flow
+$318M
Cap. Flow %
8.21%
Top 10 Hldgs %
45.33%
Holding
116
New
10
Increased
28
Reduced
12
Closed
9

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$78.8M
2
IMCR icon
Immunocore
IMCR
+$69.4M
3
TMO icon
Thermo Fisher Scientific
TMO
+$34.4M
4
ARGX icon
argenx
ARGX
+$34M
5
MASI
Masimo
MASI
+$29.9M

Top Sells

Rank Stock Value
1
GMED icon
Globus Medical
GMED
+$36.9M
2
AXNX
Axonics, Inc. Common Stock
AXNX
+$30.9M
3
LONA
LeonaBio Inc
LONA
+$25.7M
4
ITOS
iTeos Therapeutics
ITOS
+$15.7M
5
VCEL icon
Vericel Corp
VCEL
+$14.6M

Sector Composition

Rank Sector Weight
1 Healthcare 98.86%
2 Financials 0.75%
3 Industrials 0.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
1
Alnylam Pharmaceuticals
ALNY
$36.3B
$246M 6.34%
1,683,362
– –
TMO icon
2
Thermo Fisher Scientific
TMO
$211B
$237M 6.11%
435,500
+62,500
+17% +$34.4M
RCKT icon
3
Rocket Pharmaceuticals
RCKT
$348M
$217M 5.62%
15,802,802
– –
PTCT icon
4
PTC Therapeutics
PTCT
$6.37B
$202M 5.22%
5,045,307
-175,921
-3% -$6.17M
MASI
5
DELISTED
Masimo
MASI
$177M 4.56%
1,350,993
+223,400
+20% +$29.9M
ARGX icon
6
argenx
ARGX
$57.4B
$168M 4.33%
442,635
+105,657
+31% +$34M
IMCR icon
7
Immunocore
IMCR
$1.78B
$149M 3.85%
3,996,154
+2,136,683
+115% +$69.4M
ESTA icon
8
Establishment Labs
ESTA
$2.72B
$129M 3.33%
2,369,138
+50,000
+2% +$3.17M
MRTX
9
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$126M 3.27%
1,882,663
+321,166
+21% +$20.4M
ILMN icon
10
Illumina
ILMN
$29.4B
$104M 2.69%
580,178
+56,540
+11% +$14.4M
CYTK icon
11
Cytokinetics
CYTK
$11B
$101M 2.6%
2,561,182
– –
RXDX
12
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$90M 2.33%
3,189,605
+431,658
+16% +$12.5M
VCEL icon
13
Vericel Corp
VCEL
$2.3B
$88.7M 2.29%
3,522,904
-494,666
-12% -$14.6M
PEN icon
14
Penumbra
PEN
$12.5B
$87M 2.25%
698,371
+32,500
+5% +$5.16M
CLDX icon
15
Celldex Therapeutics
CLDX
$2.77B
$83.2M 2.15%
3,084,215
– –
RARE icon
16
Ultragenyx Pharmaceutical
RARE
$2.65B
$81.9M 2.12%
1,373,284
– –
NTRA icon
17
Natera
NTRA
$37.5B
$75.2M 1.94%
2,122,283
+205,000
+11% +$7.59M
RNAM
18
DELISTED
Avidity Biosciences
RNAM
$69.7M 1.8%
4,795,000
– –
AXNX
19
DELISTED
Axonics, Inc. Common Stock
AXNX
$66.9M 1.73%
1,179,965
-563,899
-32% -$30.9M
CUTR
20
DELISTED
Cutera, Inc.
CUTR
$66.4M 1.72%
1,770,400
+244,137
+16% +$12.9M
GMED icon
21
Globus Medical
GMED
$10.4B
$63M 1.63%
1,121,527
-560,764
-33% -$36.9M
PMVP icon
22
PMV Pharmaceuticals
PMVP
$66.1M
$62.6M 1.62%
4,395,677
+523,523
+14% +$7.62M
AXSM icon
23
Axsome Therapeutics
AXSM
$12.4B
$62M 1.6%
1,618,819
– –
ACAD icon
24
Acadia Pharmaceuticals
ACAD
$4.25B
$59.5M 1.54%
+4,224,109
New +$78.8M
ACET icon
25
Adicet Bio
ACET
$72.8M
$57.7M 1.49%
246,955
+60,112
+32% +$13.2M
1
2 3 4 5

Similar funds

MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.95B AUM 30.22% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RTW Investments's Q2 2022 Portfolio in Review

As of Q2 2022, RTW Investments held 116 positions worth $3.87B, down 20% from $4.83B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

RTW Investments deployed $318M of net new capital in Q2 2022, opening 10 new positions and adding to 28 existing holdings. Its largest new stake was Acadia Pharmaceuticals: 4,224,109 shares worth $59.5M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Globus Medical, an estimated $36.9M trimmed.

  • RTW Investments's largest Q2 2022 buy was Acadia Pharmaceuticals: 4,224,109 shares worth $59.5M.
  • RTW Investments added most to Immunocore in Q2 2022, an estimated $69.4M increase.
  • RTW Investments's biggest Q2 2022 reduction was Globus Medical, cutting an estimated $36.9M.
  • RTW Investments fully exited LeonaBio Inc in Q2 2022, selling an estimated $25.7M.
  • RTW Investments's ten largest holdings make up 45% of its $3.87B portfolio in Q2 2022.
  • RTW Investments opened 10 new positions and closed 9 in Q2 2022.
  • RTW Investments's portfolio value fell 20% quarter-over-quarter to $3.87B.

Based on RTW Investments's 13F filing for Q2 2022, filed 15 Aug 2022.